Phase Bio

PhaseBio is a clinical-stage biopharmaceutical company committed to developing improved biotherapeutics for the treatment of orphan diseases, with an initial focus on cardiopulmonary indications. Their pipeline includes therapies that leverage our proprietary elastin-like polypeptide (ELP) technology to enable less-frequent dosing and better patient compliance, as well as a reversal agent for the antiplatelet therapy ticagrelor.